Publicaciones en las que colabora con Juan Carlos Prieto Villapún (24)

2005

  1. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue

    Gynecological Endocrinology, Vol. 20, Núm. 6, pp. 327-333

  2. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K

    Prostate, Vol. 63, Núm. 1, pp. 44-55

2004

  1. Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells

    Bioscience Reports, Vol. 24, Núm. 1, pp. 11-21

  2. PACAP expression and distribution in human breast cancer and healthy tissue

    Cancer Letters, Vol. 205, Núm. 2, pp. 189-195

  3. Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells

    Regulatory Peptides, Vol. 119, Núm. 1-2, pp. 69-75

2003

  1. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue

    Peptides, Vol. 24, Núm. 6, pp. 893-902

  2. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal

    British Journal of Pharmacology, Vol. 139, Núm. 5, pp. 1050-1058

  3. VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: A study in biopsy specimens

    Peptides, Vol. 24, Núm. 3, pp. 429-436

2002

  1. Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues

    Regulatory Peptides, Vol. 110, Núm. 1, pp. 9-15

2001

  1. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors

    Cellular Signalling, Vol. 13, Núm. 12, pp. 887-894

  2. Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation

    Prostate, Vol. 47, Núm. 4, pp. 285-292

2000

  1. Immunohistochemical and immunochemical evidence for expression of human lung PACAP/VIP receptors

    Annals of the New York Academy of Sciences

  2. Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung

    Peptides, Vol. 21, Núm. 2, pp. 265-269

1999

  1. Effects of chronic ethanol ingestion on the vasoactive intestinal peptide receptor-effector system from rat seminal vesicle membranes

    Alcoholism: Clinical and Experimental Research, Vol. 23, Núm. 2, pp. 318-323

1998

  1. Cyclosporin A induces apoptosis in rat hepatocytes in culture

    Archives of Toxicology, Vol. 72, Núm. 9, pp. 559-565

  2. G-protein regulation of adenylate cyclase activity in rat prostatic membranes after chronic ethanol ingestion

    Prostate, Vol. 36, Núm. 4, pp. 226-234

  3. Inhibitory effect of cyclosporin A peptide on rat hepatocytes proliferation induced by mitogens

    Peptides, Vol. 19, Núm. 3, pp. 427-435

1997

  1. Identification of a protein-tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate

    FEBS Letters, Vol. 406, Núm. 1-2, pp. 42-48

1995

  1. Receptors for pituitary adenylate cyclase-activating peptide in human liver

    Journal of Clinical Endocrinology and Metabolism, Vol. 80, Núm. 8, pp. 2451-2457

1994

  1. Characterization of vasoactive intestinal peptide receptors in human liver

    BBA - Molecular Cell Research, Vol. 1221, Núm. 2, pp. 193-198